That is what I don't understand. The valuation that is there has to be real because it is pre Covid, so it actually should be more, not less I would think. That being the case, what I cannot understand is why no company is even interested in a merger or just buying it outright and getting the cancer patents out of it.

For some of these companies, buying NGIO would be a drop in the bucket....